美国食品和药物管理局批准了阿斯特拉泽内卡首款用于12岁以上患者的三重治疗喘吸入器. FDA approves AstraZeneca's first triple therapy asthma inhaler for patients 12+.

美国食品和药物管理局已批准AstraZeneca的新型单吸入器三重疗法Breztri Aerosphere用于治疗12岁及以上患者的喘. AstraZeneca’s new single-inhaler triple therapy, Breztri Aerosphere, has been approved by the FDA for treating asthma in patients 12 and older. 这是第一种固定的剂量组合,其中包括类固醇,长效支气管扩展剂和长效肌抗体. It is the first fixed-dose combination of a steroid, a long-acting bronchodilator, and a long-acting muscarinic antagonist. 临床试验显示,与其他疗法相比,它显著改善肺功能,并用于维持治疗,而不是紧急救治. Clinical trials showed it significantly improves lung function compared to other therapies and is intended for maintenance, not emergency relief.